Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics
- PMID: 20008701
- PMCID: PMC2891174
- DOI: 10.1001/archinternmed.2009.426
Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics
Abstract
Background: Randomized efficacy clinical trials conducted in research settings may not accurately reflect the benefits of tobacco dependence treatments when used in real-world clinical settings. Effectiveness trials (eg, in primary care settings) are needed to estimate the benefits of cessation treatments in real-world use.
Methods: A total of 1346 primary care patients attending routine appointments were recruited by medical assistants in 12 primary care clinics. Patients were randomly assigned to 5 active pharmacotherapies: 3 monotherapies (nicotine patch, nicotine lozenge, and bupropion hydrochloride sustained release [SR]) and 2 combination therapies (patch + lozenge and bupropion SR + lozenge). Patients were referred to a telephone quit line for cessation counseling. Primary outcomes included 7-day point prevalence abstinence at 1 week, 8 weeks, and 6 months after quitting and number of days to relapse.
Results: Among 7128 eligible smokers (> or =10 cigarettes per day) attending routine primary care appointments, 1346 (18.9%) were enrolled in the study. Six-month abstinence rates for the 5 active pharmacotherapies were the following: bupropion SR, 16.8%; lozenge, 19.9%; patch, 17.7%; patch + lozenge, 26.9%; and bupropion SR + lozenge, 29.9%. Bupropion SR + lozenge was superior to all of the monotherapies (odds ratio, 0.46-0.56); patch + lozenge was superior to patch and bupropion monotherapies (odds ratio, 0.56 and 0.54, respectively).
Conclusions: One in 5 smokers attending a routine primary care appointment was willing to make a serious quit attempt that included evidence-based counseling and medication. In this comparative effectiveness study of 5 tobacco dependence treatments, combination pharmacotherapy significantly increased abstinence compared with monotherapies. Provision of free cessation medications plus quit line counseling arranged in the primary care setting holds promise for assisting large numbers of smokers to quit. Trial Registration clinicaltrials.gov Identifier: NCT00296647.
Figures
Similar articles
-
A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.Arch Gen Psychiatry. 2009 Nov;66(11):1253-62. doi: 10.1001/archgenpsychiatry.2009.142. Arch Gen Psychiatry. 2009. PMID: 19884613 Free PMC article. Clinical Trial.
-
A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Clin Ther. 2008. PMID: 18555928 Review.
-
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.JAMA. 2016 Jan 26;315(4):371-9. doi: 10.1001/jama.2015.19284. JAMA. 2016. PMID: 26813210 Free PMC article. Clinical Trial.
-
Smoking cessation in smokers who smoke menthol and non-menthol cigarettes.Addiction. 2014 Dec;109(12):2107-17. doi: 10.1111/add.12661. Epub 2014 Jul 21. Addiction. 2014. PMID: 24938369 Free PMC article. Clinical Trial.
-
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD013308. doi: 10.1002/14651858.CD013308. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2023 Jun 19;6:CD013308. doi: 10.1002/14651858.CD013308.pub2. PMID: 30997928 Free PMC article. Updated.
Cited by
-
Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.Front Psychiatry. 2018 Sep 19;9:428. doi: 10.3389/fpsyt.2018.00428. eCollection 2018. Front Psychiatry. 2018. PMID: 30283363 Free PMC article.
-
Clinical practice. Treating smokers in the health care setting.N Engl J Med. 2011 Sep 29;365(13):1222-31. doi: 10.1056/NEJMcp1101512. N Engl J Med. 2011. PMID: 21991895 Free PMC article. Review.
-
Obstructive Sleep Apnea and Smoking Increase the Risk of Cardiovascular Disease: Smoking Cessation Pharmacotherapy.J Clin Med. 2023 Dec 8;12(24):7570. doi: 10.3390/jcm12247570. J Clin Med. 2023. PMID: 38137639 Free PMC article. Review.
-
Paths to tobacco abstinence: A repeated-measures latent class analysis.J Consult Clin Psychol. 2015 Aug;83(4):696-708. doi: 10.1037/ccp0000017. Epub 2015 Apr 13. J Consult Clin Psychol. 2015. PMID: 25867447 Free PMC article. Clinical Trial.
-
Nicotine replacement therapies: patient safety and persistence.Patient Relat Outcome Meas. 2011 Jul;2:111-7. doi: 10.2147/PROM.S11545. Epub 2011 Jun 14. Patient Relat Outcome Meas. 2011. PMID: 22915971 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Annual smoking attributable mortality, years of potential life lost, and productivity losses — United States, 1997-2001. MMWR Morb Mortal Wkly Rep. 2005;54(25):625–628. - PubMed
-
- Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. 2007;33(6 Suppl):S318–26. - PubMed
-
- Thorne SL, Malarcher A, Maurice E, Caraballa R. Cigarette smoking among adults - - United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(45):1221–1226. - PubMed
-
- Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: USDHHS, U.S. Public Health Service; 2008.
-
- Conroy MB, Majchrzak NE, Regan S, Silverman CB, Schneider LI, Rigotti NA. The association between patient-reported receipt of tobacco intervention at a primary care visit and smokers' satisfaction with their health care. Nicotine Tob Res. 2005;7(Suppl 1):S29–S34. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials